Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
S&P Global
SPGI
|
+$677M |
| 2 |
AGN
Allergan plc
AGN
|
+$437M |
| 3 |
Qualcomm
QCOM
|
+$387M |
| 4 |
lululemon athletica
LULU
|
+$366M |
| 5 |
NVIDIA
NVDA
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Under Armour
UAA
|
+$1.03B |
| 2 |
Abbott
ABT
|
+$767M |
| 3 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$627M |
| 4 |
Meta Platforms (Facebook)
META
|
+$520M |
| 5 |
Nike
NKE
|
+$454M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.09% |
| 2 | Healthcare | 16.64% |
| 3 | Technology | 14.97% |
| 4 | Communication Services | 12.63% |
| 5 | Financials | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
PUT
iShares US Healthcare ETF
IYH
$3.46B
| $8.29M | 0.01% |
279,540
-271,775
| -49% | -$7.94M |
|
|
ZEN
477
DELISTED
ZENDESK INC
ZEN
| $8.14M | 0.01% |
+308,711
| New | +$7.45M |
|
478
Chefs' Warehouse
CHEF
$4.07B
| $8.08M | 0.01% |
+505,166
| New | +$8.6M |
|
479
Corvus Pharmaceuticals
CRVS
$1.12B
| $8.07M | 0.01% |
570,481
+106,349
| +23% | +$1.44M |
|
480
HubSpot
HUBS
$12.2B
| $7.87M | 0.01% |
+181,208
| New | +$8.22M |
|
|
FENX
481
DELISTED
Fenix Parts, Inc.
FENX
| $7.77M | 0.01% |
1,976,971
+13,784
| +0.7% | +$58.3K |
|
482
Planet Fitness
PLNT
$4.43B
| $7.55M | 0.01% |
+400,000
| New | +$6.74M |
|
|
RRMS
483
DELISTED
ROSE ROCK MIDSTREAM L P COM UNIT REPSTG LTD (DE)
RRMS
| $7.5M | 0.01% |
284,069
+57,379
| +25% | +$1.17M |
|
|
CIE
484
DELISTED
Cobalt International Energy, Inc
CIE
| $7.31M | 0.01% |
363,545
-22,294
| -6% | -$858K |
|
|
GWPH
485
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $7.13M | 0.01% |
+77,871
| New | +$6.55M |
|
486
Agios Pharmaceuticals
AGIO
$2.14B
| $7.12M | 0.01% |
169,974
-312,123
| -65% | -$15.4M |
|
|
DCOY
487
Decoy Therapeutics
DCOY
$2.19M
| $7.05M | 0.01% |
1
| – | – |
|
488
PUT
iShares Biotechnology ETF
IBB
$9.54B
| $6.96M | 0.01% |
81,189
-35,919
| -31% | -$3.22M |
|
489
Provident Financial Services
PFS
$3.15B
| $6.89M | 0.01% |
350,968
-498,788
| -59% | -$9.93M |
|
|
AVXS
490
DELISTED
AveXis, Inc. Common Stock
AVXS
| $6.83M | 0.01% |
179,783
-218
| -0.1% | -$7.37K |
|
491
Spyre Therapeutics
SYRE
$8.68B
| $6.69M | 0.01% |
+55,523
| New | +$10.6M |
|
|
PSXP
492
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $6.42M | 0.01% |
114,904
-20,010
| -15% | -$1.12M |
|
493
MPLX
MPLX
$60.1B
| $5.92M | 0.01% |
+176,030
| New | +$5.59M |
|
494
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $5.7M | 0.01% |
+298,900
| New | +$5.54M |
|
|
AM
495
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $5.68M | 0.01% |
203,847
+9,265
| +5% | +$224K |
|
|
DSCI
496
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $5.57M | 0.01% |
1,413,534
-953
| -0.1% | -$3.56K |
|
497
MacroGenics
MGNX
$244M
| $5.29M | 0.01% |
196,162
-273
| -0.1% | -$6.16K |
|
498
USA Compression Partners
USAC
$3.74B
| $5.28M | 0.01% |
360,301
+16,729
| +5% | +$235K |
|
499
Syndax Pharmaceuticals
SNDX
$1.74B
| $5.25M | 0.01% |
537,545
+76,653
| +17% | +$1.05M |
|
500
Norfolk Southern
NSC
$76.1B
| $5.16M | 0.01% |
60,549
+12,785
| +27% | +$1.09M |
|
Similar funds
Jennison Associates's Q2 2016 Portfolio in Review
As of Q2 2016, Jennison Associates held 691 positions worth $91.1B, down 4.3% from $95.3B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Jennison Associates withdrew a net $4.67B in Q2 2016, closing 61 positions and reducing 333 holdings. Its most notable exit was MCGRAW-HILL FINANCIAL INC COM, an estimated $627M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Jennison Associates opened a new position in S&P Global worth $677M.
- Jennison Associates's largest Q2 2016 buy was S&P Global: 6,307,763 shares worth $677M.
- Jennison Associates added most to Allergan plc in Q2 2016, an estimated $437M increase.
- Jennison Associates's biggest Q2 2016 reduction was Under Armour, cutting an estimated $1.03B.
- Jennison Associates fully exited MCGRAW-HILL FINANCIAL INC COM in Q2 2016, selling an estimated $627M.
- Jennison Associates's ten largest holdings make up 23% of its $91.1B portfolio in Q2 2016.
- Jennison Associates opened 83 new positions and closed 61 in Q2 2016.
- Jennison Associates's portfolio value fell 4.3% quarter-over-quarter to $91.1B.
Based on Jennison Associates's 13F filing for Q2 2016, filed 3 Aug 2016.